Cytophage Technologies (TSXV:CYTO) Total Current Assets : C$6.25 Mil (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Cytophage Technologies Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Cytophage Technologies's total current assets for the quarter that ended in Mar. 2024 was C$6.25 Mil.

Cytophage Technologies Total Current Assets Historical Data

The historical data trend for Cytophage Technologies's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cytophage Technologies Total Current Assets Chart

Cytophage Technologies Annual Data

Trend

Dec21

Dec22

Dec23

Total Current Assets

4.96

2.76

5.46

Cytophage Technologies Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Total Current Assets	Get a 7-Day Free Trial			2.76	-	0.85	5.46	6.25

Cytophage Technologies Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Cytophage Technologies's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	5.434	+	0.025	+	0	+	0.0019999999999998
	=	5.46

Cytophage Technologies's Total Current Assets for the quarter that ended in Mar. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	5.568	+	0.396	+	0	+	0.284
	=	6.25

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Cytophage Technologies (TSXV:CYTO) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Cytophage Technologies's Liquidation Value for the quarter that ended in Mar. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	5.568	-	2.24	+	0.75 * 0.165	+	0.5 * 0
=	3.45

Cytophage Technologies Total Current Assets Related Terms

Thank you for viewing the detailed overview of Cytophage Technologies's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Cytophage Technologies (TSXV:CYTO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cytophage Technologies Ltd (TSXV:CYTO) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Cytophage Technologies Ltd is a Canadian biotechnology company that uses molecular genetic techniques and synthetic biology to create effective bacteriophages to address bacterial challenges affecting animal health, human health, and food security. Bacteriophages are viruses that have evolved to specifically target and destroy strictly bacterial cells and are safe for humans, animals, and plants. To combat dangerous bacteria company generates phages to address specific bacterial infections, including strains resistant to antibiotics. It has also developed a 'phage-display' methodology to develop vaccine-like products using bacteriophages for a number of potential applications in human and animal health.